

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

Mouse Anti-Histone H3, acetyl (Lys4), trimethyl Monoclonal Antibody, Unconjugated, Clone CMA304

RRID:AB_1977251

Type: Antibody

Proper Citation

Millipore Cat# 05-1339, RRID:AB_1977251

Antibody Information

URL: http://antibodyregistry.org/AB_1977251

Proper Citation: Millipore Cat# 05-1339, RRID:AB_1977251

Target Antigen: Histone H3, acetyl (Lys4), trimethyl

Host Organism: mouse

Clonality: monoclonal

Comments: seller recommendations: ELISA; Immunocytochemistry; Immunoprecipitation; Other; Western Blot; Multiplexing, ELISA, Immunocytochemistry, Immunoprecipitation, Western Blotting

Antibody Name: Mouse Anti-Histone H3, acetyl (Lys4), trimethyl Monoclonal Antibody, Unconjugated, Clone CMA304

Description: This monoclonal targets Histone H3, acetyl (Lys4), trimethyl

Target Organism: other, feline, chickenavian, rat, hamster, simian, xenopus, donkey, porcine, canine, goat, vertebrates, horse, mouse, rabbit, bovine, human, sheep

Clone ID: Clone CMA304

Antibody ID: AB_1977251

Vendor: Millipore

Catalog Number: 05-1339

Record Creation Time: 20231110T051149+0000

Record Last Update: 20260831T222112+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Histone H3, acetyl (Lys4), trimethyl Monoclonal Antibody, Unconjugated, Clone CMA304.

No alerts have been found for Mouse Anti-Histone H3, acetyl (Lys4), trimethyl Monoclonal Antibody, Unconjugated, Clone CMA304.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Citron F, et al. (2026) DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer. Cancer research, 86(12), 2837.

Mei H, et al. (2026) H2AK119ub1-MLL2 counteraction underlies heritable H3K27me3 formation in oocytes. Molecular cell, 86(9), 1691.

Li HT, et al. (2023) RNA mis-splicing drives viral mimicry response after DNMTi therapy in SETD2-mutant kidney cancer. Cell reports, 42(1), 112016.

Blanco MA, et al. (2021) Chromatin-state barriers enforce an irreversible mammalian cell fate decision. Cell reports, 37(6), 109967.